Loading...

Lewis Rubin

TitleEmeritus Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9300 Campus Point Drive #7381
La Jolla CA 92037
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ. Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. J Heart Lung Transplant. 2018 Sep 09. PMID: 30209017.
      View in: PubMed
    2. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Torbicki A, Rubin LJ, Simonneau G. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018; 13(3):e0193226. PMID: 29590122.
      View in: PubMed
    3. McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, Ghofrani HA, Jansa P, Lang IM, Mehta S, Pulido T, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A, Tapson VF, Perchenet L, Preiss R, Verweij P, Rubin LJ, Galiè N. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. J Am Coll Cardiol. 2018 Feb 20; 71(7):752-763. PMID: 29447737.
      View in: PubMed
    4. Rubin LJ. Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era: Importance of Serial Hemodynamic Measurements. Circulation. 2018 Feb 13; 137(7):705-706. PMID: 29440197.
      View in: PubMed
    5. Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018 Feb; 51(2). PMID: 29437943.
      View in: PubMed
    6. Rubin LJ. Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. Ann Am Thorac Soc. 2018 Feb; 15(Supplement_1):S42-S44. PMID: 29461887.
      View in: PubMed
    7. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Gaine S. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb; 18(1):37-47. PMID: 29307087.
      View in: PubMed
    8. Parikh KS, Gray MP, Rubin LJ, Badesch D, Krasuski RA. Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulm Circ. 2018 Jan-Mar; 8(1):2045893217743184. PMID: 29534640.
      View in: PubMed
    9. McLaughlin V, Bacchetta M, Badesch D, Benza R, Burger C, Chin K, Frantz R, Frost A, Hemnes A, Kim NH, Rosenzweig EB, Rubin L. Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin. 2018 Feb; 34(2):263-273. PMID: 29132217.
      View in: PubMed
    10. Chan SY, Rubin LJ. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Eur Respir Rev. 2017 Dec 31; 26(146). PMID: 29263174.
      View in: PubMed
    11. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF, Rubin LJ. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018 Mar; 37(3):401-408. PMID: 29096938.
      View in: PubMed
    12. Rubin LJ. Targeting bone morphogenic protein receptor 2 (BMPR2) signalling to treat pulmonary arterial hypertension. Eur Respir J. 2017 Sep; 50(3). PMID: 28893872.
      View in: PubMed
    13. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani HA, Lang IM, McLaughlin V, Preiss R, Rubin LJ, Simonneau G, Sitbon O, Tapson VF, Hoeper MM. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017 Aug; 50(2). PMID: 28818881.
      View in: PubMed
    14. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, Le Brun FO, Mehta S, Perchenet L, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017 04 14; 38(15):1147-1155. PMID: 28329315.
      View in: PubMed
    15. Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017 Jul; 76(7):1219-1227. PMID: 28039187.
      View in: PubMed
    16. Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. J Heart Lung Transplant. 2017 May; 36(5):509-519. PMID: 28190787.
      View in: PubMed
    17. Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016 Dec; 25(142):381-389. PMID: 27903660.
      View in: PubMed
    18. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016 11; 4(11):894-901. PMID: 27745818.
      View in: PubMed
    19. Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani HA, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017 Jan; 151(1):106-118. PMID: 27671974.
      View in: PubMed
    20. Rubin LJ. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J. 2016 Sep; 48(3):617-8. PMID: 27581405.
      View in: PubMed
    21. Ben-Yehuda O, Rubin LJ. Pulmonary Hypertension Overlap Syndromes: A Real Entity? J Am Coll Cardiol. 2016 Jul 26; 68(4):379-81. PMID: 27443434.
      View in: PubMed
    22. Rubin LJ. Are Animal Models of Pulmonary Hypertension Relevant to the Clinical Disease? J Am Coll Cardiol. 2016 May 03; 67(17):2047-9. PMID: 27126532.
      View in: PubMed
    23. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. Chest. 2016 Jul; 150(1):27-34. PMID: 27396777.
      View in: PubMed
    24. Rubin LJ. Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC Cardiovasc Interv. 2015 Dec 28; 8(15):2024-2025. PMID: 26738674.
      View in: PubMed
    25. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24; 373(26):2522-33. PMID: 26699168.
      View in: PubMed
    26. Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. Improving patient outcomes in pulmonary hypertension. Eur Respir Rev. 2015 Dec; 24(138):550-1. PMID: 26621969.
      View in: PubMed
    27. Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun FO, Mehta S, Perchenet L, Pulido T, Sastry BK, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015 Dec; 46(6):1711-20. PMID: 26493786; PMCID: PMC4664609.
    28. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015 Aug 27; 373(9):834-44. PMID: 26308684.
      View in: PubMed
    29. Vachiery JL, Rubin LJ. Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. Eur Respir J. 2015 Aug; 46(2):297-8. PMID: 26232474.
      View in: PubMed
    30. Rubin LJ. The beta-adrenergic receptor in pulmonary arterial hypertension: a novel therapeutic target? J Am Coll Cardiol. 2015 Feb 24; 65(7):681-3. PMID: 25677429.
      View in: PubMed
    31. Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015 May; 45(5):1303-13. PMID: 25614164.
      View in: PubMed
    32. Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. J Heart Lung Transplant. 2015 Mar; 34(3):338-47. PMID: 25703961.
      View in: PubMed
    33. McLaughlin V, Simonneau G, Galiè N, Rubin LJ. New horizons in pulmonary arterial hypertension management. Eur Respir Rev. 2014 Dec; 23(134):408-9. PMID: 25445938.
      View in: PubMed
    34. Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, Mehta S, Pulido T, Rubin LJ, Sastry BK, Simonneau G, Sitbon O, Souza R, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015 Jan; 3(1):1-8. PMID: 25457902.
      View in: PubMed
    35. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. [Updated treatment algorithm of pulmonary arterial hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:78-94. PMID: 25697036.
      View in: PubMed
    36. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. [New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars. 2014 Oct; 42 Suppl 1:106-18. PMID: 25697038.
      View in: PubMed
    37. Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med. 2014 Jul; 2(7):573-82. PMID: 24898750.
      View in: PubMed
    38. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Jul; 33(7):689-97. PMID: 24815795.
      View in: PubMed
    39. Simonneau G, Galiè N, Jansa P, Meyer GM, Al-Hiti H, Kusic-Pajic A, Lemarié JC, Hoeper MM, Rubin LJ. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol. 2014 Mar 15; 172(2):332-9. PMID: 24525158.
      View in: PubMed
    40. Pulido T, Rubin LJ, Simonneau G. Macitentan and pulmonary arterial hypertension. N Engl J Med. 2014 01 02; 370(1):82-3. PMID: 24382071.
      View in: PubMed
    41. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D60-72. PMID: 24355643.
      View in: PubMed
    42. Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl):D82-91. PMID: 24355645; PMCID: PMC4117578.
    43. Ghofrani HA, Simonneau G, Rubin LJ. Riociguat for pulmonary hypertension. N Engl J Med. 2013 12 05; 369(23):2268. PMID: 24304056.
      View in: PubMed
    44. Rubin LJ, Galiè N, Simonneau G, McLaughlin V. A paradigm shift in pulmonary arterial hypertension management. Eur Respir Rev. 2013 Dec; 22(130):423-6. PMID: 24293459.
      View in: PubMed
    45. Dingemanse J, Sidharta PN, Maddrey WC, Rubin LJ, Mickail H. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2014 Mar; 13(3):391-405. PMID: 24261583.
      View in: PubMed
    46. Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. Am Heart J. 2014 Feb; 167(2):218-225.e1. PMID: 24439983.
      View in: PubMed
    47. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, Kotlyar E, McSwain CS, Laliberte K, Arneson C, Rubin LJ. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013 Sep; 144(3):952-958. PMID: 23669822.
      View in: PubMed
    48. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29; 369(9):809-18. PMID: 23984728.
      View in: PubMed
    49. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25; 369(4):330-40. PMID: 23883378.
      View in: PubMed
    50. Rubin LJ. Cor pulmonale revisited. J Am Coll Cardiol. 2013 Sep 17; 62(12):1112-1113. PMID: 23850928.
      View in: PubMed
    51. Rubin LJ. Robyn J. Barst, MD. Eur Respir J. 2013 Jul; 42(1):16-7. PMID: 23971081.
      View in: PubMed
    52. Rubin LJ. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation. 2013 Jul 30; 128(5):475-6. PMID: 23775259.
      View in: PubMed
    53. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest. 2013 Feb 01; 143(2):324-332. PMID: 22910999.
      View in: PubMed
    54. Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013 Feb; 31(1):38-44. PMID: 22970909; PMCID: PMC3561685.
    55. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013 Feb 05; 127(5):624-33. PMID: 23307827.
      View in: PubMed
    56. Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013 Jan; 11(1):13-25. PMID: 23259441.
      View in: PubMed
    57. Rubin LJ. Pulmonary hypertension: current management and future directions. Handb Exp Pharmacol. 2013; 218:551-5. PMID: 24092355.
      View in: PubMed
    58. Humbert M, Souza R, Galiè N, McLaughlin V, Simonneau G, Rubin L. Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev. 2012 Dec 01; 21(126):267-70. PMID: 23204116.
      View in: PubMed
    59. Galiè N, Rubin L, Simonneau G. Developing a heart score: next steps. Am J Cardiol. 2012 Sep 15; 110(6 Suppl):49S-51S. PMID: 22921032.
      View in: PubMed
    60. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? Am J Respir Crit Care Med. 2012 Sep 01; 186(5):396-7. PMID: 22942342.
      View in: PubMed
    61. Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012 Sep 01; 21(125):234-8. PMID: 22941888.
      View in: PubMed
    62. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012 Oct 15; 91(13-14):528-39. PMID: 22967485.
      View in: PubMed
    63. Vizza CD, Fedele F, Pezzuto B, Rubin LJ. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opin Drug Saf. 2012 Nov; 11(6):1003-11. PMID: 22861496.
      View in: PubMed
    64. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 2012 Oct 15; 91(13-14):517-21. PMID: 22884806.
      View in: PubMed
    65. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol. 2012 Nov 15; 110(10):1546-50. PMID: 22853986.
      View in: PubMed
    66. Rubin LJ. Exercise training for pulmonary hypertension: another prescription to write? Eur Respir J. 2012 Jul; 40(1):7-8. PMID: 22753832.
      View in: PubMed
    67. Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther. 2012; 6:19-28. PMID: 22291467; PMCID: PMC3267519.
    68. Rubin LJ. Combination therapy for pulmonary artery hypertension: what is the evidence? Cardiology. 2011; 120(3):172-3. PMID: 22248863.
      View in: PubMed
    69. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. 2011 Dec; 30(12):1327-33. PMID: 22055098.
      View in: PubMed
    70. Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tröster N, Hesse C, Rubin L, Olschewski H. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012 Apr; 64(4):1257-62. PMID: 22127844.
      View in: PubMed
    71. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012 Feb; 71(2):249-52. PMID: 21998119.
      View in: PubMed
    72. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O. Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2011 Nov; 38(11):2419-27. PMID: 21965635.
      View in: PubMed
    73. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O. Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Res Ther. 2011 Jun 20; 13(3):114. PMID: 21699746; PMCID: PMC3218892.
    74. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012 Apr; 30(2):93-9. PMID: 21884013.
      View in: PubMed
    75. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011 Nov; 140(5):1274-1283. PMID: 21546436.
      View in: PubMed
    76. Rubin LJ, Morrell NW. New frontiers in pulmonary hypertension. Expert Rev Respir Med. 2011 Apr; 5(2):139-40. PMID: 21510723.
      View in: PubMed
    77. Rubin LJ. Metabolic dysfunction in the pathogenesis of pulmonary hypertension. Cell Metab. 2010 Oct 06; 12(4):313-4. PMID: 20889122.
      View in: PubMed
    78. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S47-52. PMID: 20576214.
      View in: PubMed
    79. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ. Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010 Jun; 137(6 Suppl):85S-94S. PMID: 20522584.
      View in: PubMed
    80. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE. Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis. 2010 Jul; 69(7):1360-3. PMID: 20472586.
      View in: PubMed
    81. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 04; 55(18):1915-22. PMID: 20430262.
      View in: PubMed
    82. Galiè N, Simonneau G, Barst RJ, Badesch D, Rubin L. Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S11-9. PMID: 20375660.
      View in: PubMed
    83. Rubin L, Simonneau G. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med. 2010 May; 16 Suppl 1:S43-6. PMID: 20375664.
      View in: PubMed
    84. Park MH, Rubin LJ. Editor's response to "ethical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertension". J Heart Lung Transplant. 2010 Jul; 29(7):827-8. PMID: 20417131.
      View in: PubMed
    85. Galiè N, Rubin LJ, Simonneau G. Phosphodiesterase inhibitors for pulmonary hypertension. N Engl J Med. 2010 Feb 11; 362(6):559-60; author reply 560. PMID: 20175298.
      View in: PubMed
    86. Park MH, Rubin LJ. The globalization of clinical trials in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):157-8. PMID: 20113908.
      View in: PubMed
    87. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol. 2010 Jan; 37(1):105-15. PMID: 19955042.
      View in: PubMed
    88. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Nov 17; 54(21):1971-81. PMID: 19909879.
      View in: PubMed
    89. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol. 2009 Oct; 36(10):2356-61. PMID: 19820225.
      View in: PubMed
    90. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009 Oct; 36(10):2244-9. PMID: 19723905.
      View in: PubMed
    91. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct; 30(20):2493-537. PMID: 19713419.
      View in: PubMed
    92. Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Tröster N, Hesse C, Salmhofer W, Graninger W, Gruenig E, Rubin LJ, Olschewski H. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):881-6. PMID: 19679693.
      View in: PubMed
    93. Adamali H, Gaine SP, Rubin LJ. Medical treatment of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009 Aug; 30(4):484-92. PMID: 19634087.
      View in: PubMed
    94. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S78-84. PMID: 19555861; PMCID: PMC3686287.
    95. Ghofrani HA, Barst RJ, Benza RL, Champion HC, Fagan KA, Grimminger F, Humbert M, Simonneau G, Stewart DJ, Ventura C, Rubin LJ. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30; 54(1 Suppl):S108-17. PMID: 19555854; PMCID: PMC4883573.
    96. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619. PMID: 19389575.
      View in: PubMed
    97. Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, Jiang W, Vangala N, Landsberg JW, Wang JY, Thistlethwaite PA, Channick RN, Robbins IM, Loyd JE, Ghofrani HA, Grimminger F, Schermuly RT, Cahalan MD, Rubin LJ, Yuan JX. A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation. 2009 May 05; 119(17):2313-22. PMID: 19380626; PMCID: PMC2749566.
    98. Rubin LJ. Endothelin and the systemic circulation a therapeutic target worth revisiting? J Am Coll Cardiol. 2009 Apr 14; 53(15):1318-9. PMID: 19358947.
      View in: PubMed
    99. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94. PMID: 19332472.
      View in: PubMed
    100. Yao W, Firth AL, Sacks RS, Ogawa A, Auger WR, Fedullo PF, Madani MM, Lin GY, Sakakibara N, Thistlethwaite PA, Jamieson SW, Rubin LJ, Yuan JX. Identification of putative endothelial progenitor cells (CD34+CD133+Flk-1+) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009 Jun; 296(6):L870-8. PMID: 19286928; PMCID: PMC2692803.
    101. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16; 52(25):2127-34. PMID: 19095129.
      View in: PubMed
    102. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Ghofrani HA, Olschewski H. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009 Feb; 22(1):50-6. PMID: 19071225.
      View in: PubMed
    103. Oudiz RJ, Rubin LJ. Exercise-induced pulmonary arterial hypertension: a new addition to the spectrum of pulmonary vascular diseases. Circulation. 2008 Nov 18; 118(21):2120-1. PMID: 19015412.
      View in: PubMed
    104. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 Oct 21; 149(8):521-30. PMID: 18936500.
      View in: PubMed
    105. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009 Jan; 135(1):122-129. PMID: 18812445.
      View in: PubMed
    106. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009 Jan; 135(1):130-136. PMID: 18719056.
      View in: PubMed
    107. Ogawa A, Firth AL, Yao W, Rubin LJ, Yuan JX. Prednisolone inhibits PDGF-induced nuclear translocation of NF-kappaB in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2008 Oct; 295(4):L648-57. PMID: 18708631; PMCID: PMC2575943.
    108. Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008 Oct; 134(4):775-82. PMID: 18625676.
      View in: PubMed
    109. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, Schermuly RT, Grimminger F, Rubin LJ, Olschewski H, Seeger W, Ghofrani HA. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008 Oct; 21(5):824-32. PMID: 18657627.
      View in: PubMed
    110. Rubin LJ. BMPR2 mutation and outcome in pulmonary arterial hypertension: clinical relevance to physicians and patients. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1300-1. PMID: 18522952.
      View in: PubMed
    111. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum. 2008 Jun 15; 59(6):867-75. PMID: 18512721.
      View in: PubMed
    112. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10; 117(23):3010-9. PMID: 18506008.
      View in: PubMed
    113. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Apr 22; 51(16):1527-38. PMID: 18420094.
      View in: PubMed
    114. Rubin LJ. Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008 Feb; 34(1):191-7; viii. PMID: 18329540.
      View in: PubMed
    115. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007 Dec; 34(12):2417-22. PMID: 17985403.
      View in: PubMed
    116. Chin KM, Channick RN, Kim NH, Rubin LJ. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007 Sep; 132(3):786-92. PMID: 17646224.
      View in: PubMed
    117. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 Jun; 131(6):1917-28. PMID: 17565025.
      View in: PubMed
    118. Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007 Jun 15; 175(12):1272-9. PMID: 17379852; PMCID: PMC2176091.
    119. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, O'connor DT, Yuan JX. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 May; 292(5):C1837-53. PMID: 17267549.
      View in: PubMed
    120. Rubin LJ, Black CM, Denton CP, Seibold JR. Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Res Ther. 2007; 9 Suppl 2:S10. PMID: 17767739; PMCID: PMC2072884.
    121. Zhang S, Dong H, Rubin LJ, Yuan JX. Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007 Jun; 292(6):C2297-305. PMID: 17192285.
      View in: PubMed
    122. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006 Dec; 130(6):1657-63. PMID: 17166979.
      View in: PubMed
    123. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, Barst RJ, Ghofrani HA, Jing ZC, Opitz C, Seyfarth HJ, Halank M, McLaughlin V, Oudiz RJ, Ewert R, Wilkens H, Kluge S, Bremer HC, Baroke E, Rubin LJ. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006 Dec 19; 48(12):2546-52. PMID: 17174196.
      View in: PubMed
    124. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006 Oct 24; 114(17):1883-91. PMID: 17060398.
      View in: PubMed
    125. Rubin LJ. Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target? Circulation. 2006 Sep 26; 114(13):1350-1. PMID: 17000920.
      View in: PubMed
    126. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, Gessler T, Schmehl T, Ghofrani HA, Schermuly RT, Grimminger F, Rubin LJ, Seeger W, Olschewski H. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006 Oct 17; 48(8):1672-81. PMID: 17045906.
      View in: PubMed
    127. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006 Oct 03; 48(7):1433-7. PMID: 17010807.
      View in: PubMed
    128. Rubin LJ, Hoeper MM, Klepetko W, Galiè N, Lang IM, Simonneau G. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc. 2006 Sep; 3(7):601-7. PMID: 16963541.
      View in: PubMed
    129. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz RJ, Robbins IM, Tapson V, Abenhaim L, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006 Sep; 152(3):521-6. PMID: 16923424.
      View in: PubMed
    130. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006 Sep; 3(7):608-14. PMID: 16963542.
      View in: PubMed
    131. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 01; 174(11):1257-63. PMID: 16946127.
      View in: PubMed
    132. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006 Apr 25; 113(16):2011-20. PMID: 16636189.
      View in: PubMed
    133. Hoeper MM, Rubin LJ. Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):499-505. PMID: 16493163.
      View in: PubMed
    134. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006; 3(1):111-5. PMID: 16493158.
      View in: PubMed
    135. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17; 353(20):2148-57. PMID: 16291984.
      View in: PubMed
    136. Laving A, Khanna A, Rubin L, Ing F, Dohil R, Lavine JE. Successful liver transplantation in a child with severe portopulmonary hypertension treated with epoprostenol. J Pediatr Gastroenterol Nutr. 2005 Oct; 41(4):466-8. PMID: 16205516.
      View in: PubMed
    137. Hsu HH, Rubin LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2005 Sep; 6(11):1921-30. PMID: 16144511.
      View in: PubMed
    138. Kim NH, Rubin LJ. Management following pulmonary thromboendarterectomy: experience versus evidence. Crit Care Med. 2005 Sep; 33(9):2132-3. PMID: 16148499.
      View in: PubMed
    139. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005 Aug 16; 143(4):282-92. PMID: 16103472.
      View in: PubMed
    140. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Aug 02; 46(3):529-35. PMID: 16053970.
      View in: PubMed
    141. Rubin LJ, Dufton C, Gerber MJ. Ambrisentan for pulmonary arterial hypertension. Future Cardiol. 2005 Jul; 1(4):425-32. PMID: 19804142.
      View in: PubMed
    142. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G. [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. Rev Esp Cardiol. 2005 May; 58(5):523-66. PMID: 15899198.
      View in: PubMed
    143. Rubin LJ. Epoprostenol and nesiritide in pulmonary hypertension. Chest. 2005 May; 127(5):1870. PMID: 15888882.
      View in: PubMed
    144. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation. 2005 Feb 08; 111(5):534-8. PMID: 15699271.
      View in: PubMed
    145. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005 Feb; 16(1):13-8. PMID: 15654194.
      View in: PubMed
    146. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec; 25(24):2243-78. PMID: 15589643.
      View in: PubMed
    147. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004 Sep 21; 101(38):13861-6. PMID: 15358862; PMCID: PMC518765.
    148. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004 Sep; 68(2):75-103. PMID: 15313118.
      View in: PubMed
    149. Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, Yuan JX. Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med. 2004 Nov 15; 170(10):1101-7. PMID: 15317671.
      View in: PubMed
    150. Rubin LJ, Naeije R. Sildenafil for enhanced performance at high altitude? Ann Intern Med. 2004 Aug 03; 141(3):233-5. PMID: 15289224.
      View in: PubMed
    151. Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004 Aug; 126(2):420-7. PMID: 15302727.
      View in: PubMed
    152. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):7S-10S. PMID: 15249491.
      View in: PubMed
    153. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl):4S-6S. PMID: 15249490.
      View in: PubMed
    154. Elliott CG, Rubin LJ. Mars or venus--is sex a risk factor for recurrent venous thromboembolism? N Engl J Med. 2004 Jun 17; 350(25):2614-6. PMID: 15201419.
      View in: PubMed
    155. Rubin LJ, Galiè N. Pulmonary arterial hypertension: a look to the future. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):89S-90S. PMID: 15194184.
      View in: PubMed
    156. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):81S-88S. PMID: 15194183.
      View in: PubMed
    157. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):62S-67S. PMID: 15194180.
      View in: PubMed
    158. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):5S-12S. PMID: 15194173.
      View in: PubMed
    159. Kim NH, Fesler P, Channick RN, Knowlton KU, Ben-Yehuda O, Lee SH, Naeije R, Rubin LJ. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation. 2004 Jan 06; 109(1):18-22. PMID: 14699009.
      View in: PubMed
    160. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003 Oct; 124(4):1612-5. PMID: 14555600.
      View in: PubMed
    161. Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, Maurer G, Lang IM. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2003 Sep; 90(3):372-6. PMID: 12958604.
      View in: PubMed
    162. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, Tapson VF, Rubin LJ. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003 Jul; 124(1):247-54. PMID: 12853530.
      View in: PubMed
    163. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Jun 18; 41(12):2119-25. PMID: 12821234.
      View in: PubMed
    164. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ, Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003 Sep; 285(3):L740-54. PMID: 12740218.
      View in: PubMed
    165. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003 Apr 16; 41(8):1380-6. PMID: 12706935.
      View in: PubMed
    166. Kerr KM, Rubin LJ. Epoprostenol therapy as a bridge to pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Chest. 2003 Feb; 123(2):319-20. PMID: 12576339.
      View in: PubMed
    167. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, Sigman J, Roscigno R, Blackburn SD, Arneson C, Rubin LJ, Rich S. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003 Feb; 41(2):293-9. PMID: 12548091.
      View in: PubMed
    168. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med. 2002 Nov 15; 166(10):1308-9. PMID: 12421739.
      View in: PubMed
    169. Williamson TL, Kim NH, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis. 2002 Nov-Dec; 45(3):203-12. PMID: 12525996.
      View in: PubMed
    170. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 01; 347(5):322-9. PMID: 12151469.
      View in: PubMed
    171. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs. 2002 Jul; 11(7):991-1002. PMID: 12084009.
      View in: PubMed
    172. Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002 May 01; 165(9):1209-16. PMID: 11991870.
      View in: PubMed
    173. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21; 346(12):896-903. PMID: 11907289.
      View in: PubMed
    174. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15; 165(6):800-4. PMID: 11897647.
      View in: PubMed
    175. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002 Feb; 26(2):194-201. PMID: 11804870.
      View in: PubMed
    176. Krick S, Platoshyn O, Sweeney M, McDaniel SS, Zhang S, Rubin LJ, Yuan JX. Nitric oxide induces apoptosis by activating K+ channels in pulmonary vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2002 Jan; 282(1):H184-93. PMID: 11748062.
      View in: PubMed
    177. Kim NH, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther. 2002 Jan; 7(1):9-19. PMID: 12000973.
      View in: PubMed